Point of care CYP2C19 genotyping after percutaneous coronary intervention.

Loss-of-function CYP2C19 variants are associated with increased cumulative ischemic outcomes warranting CYP2C19 genotyping prior to clopidogrel administration. TAILOR-PCI was an international, multicenter (40 sites), prospective, randomized trial comparing rapid point of care (POC) genotype-guided vs. conventional anti-platelet therapy. The performance of buccal-based rapid CYP2C19 genotyping performed by non-laboratory-trained staff in TAILOR-PCI was assessed. Pre-trial training and evaluation involved rapid genotyping of 373 oral samples, with 99.5% (371/373) concordance with Sanger sequencing. During TAILOR-PCI, 5302 patients undergoing PCI were randomized to POC rapid CYP2C19 *2, *3, and *17 genotyping versus no genotyping. At 12 months post-PCI, TaqMan genotyping determined 99.1% (2,364/2,385) concordance with the POC results, with 90.7-98.8% sensitivity and 99.2-99.6% specificity. In conclusion, non-laboratory personnel can be successfully trained for on-site instrument operation and POC rapid genotyping with analytical accuracy and precision across multiple international centers, thereby supporting POC genotyping in patient-care settings, such as the cardiac catheterization laboratory.Clinical Trial Registration: https://www.clinicalTrials.gov (Identifier: NCT01742117).

Characteristics and long term outcomes of patients with acute coronary syndromes due to culprit left main coronary artery disease treated with percutaneous coronary intervention.

BACKGROUND: Patients with acute coronary syndrome (ACS) due to unprotected culprit left main coronary artery disease (LMCAD) treated with percutaneous coronary intervention (PCI) are rare, high-risk, and not represented in trials. Data regarding long term outcome after PCI are limited. METHODS: Between January 2000 and December 2014, there were 8,794 patients hospitalized with unstable angina/non-ST elevation myocardial infarction (UA/NSTEMI) or ST-elevation myocardial infarction (STEMI) treated with PCI at our institution; of these, 83 (0.94%) patients were identified as having culprit LMCAD ACS. RESULTS: Of the 83 patients with unprotected LMCAD ACS, 40 patients presented with STEMI and 43 patients presented with UA/NSTEMI. As compared to LM UA/NSTEMI, LM STEMI patients were younger and had less hypertension, with a trend towards greater frequency of cardiogenic shock. Distal LM involvement was common in both groups and did not differ by ACS type. In-hospital mortality was 33% in LM STEMI and 9% in LM UA/NSTEMI (P = .009). Over median follow up of 6.3 years, long term survival rates in both groups were similar (46% for STEMI vs 51% for UA/NSTEMI; P = .50 by log-rank). CONCLUSIONS: Unprotected culprit LMCAD ACS necessitating PCI is uncommon, occurring in <1% of cases, but is associated with reduced survival, with long term follow-up noting continued and similar risk of death regardless of index ACS type.

Characteristics and Long-Term Outcomes of Patients With Prior Coronary Artery Bypass Grafting Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.

Limited data are available on characteristics and long-term outcomes of patients with coronary artery bypass grafts (CABG) undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction (STEMI). Between January 2000 to December 2014, we identified STEMI patients with prior CABG undergoing primary percutaneous coronary intervention from 3 sites. Kaplan-Meier methods to estimate survival and major adverse cardiac events (MACE) were employed and compared to a propensity matched cohort of non-CABG STEMI patients. Independent predictors of outcomes were analyzed with Cox modeling. Of the 3,212 STEMI patients identified, there were 296 (9.2%) CABG STEMI patients, having nearly similar frequencies of culprit graft (47.6%) versus culprit native (52.4%) as the infarct-related artery (IRA). At 10 years, the adjusted survival was 44% in CABG STEMI versus 55% in non-CABG STEMI (HR 1.26; 95%CI 0.86 to 1.87; p = 0.72). Survival free of MACE was lower for CABG STEMI (graft IRA, 37%; native IRA, 46%) as compared to non-CABG STEMI controls (63%) (p = 0.02). Neither CABG history nor IRA (native vs graft) was independently associated with death or MACE in multivariable analysis. Temporal trends showed no significant change in death or MACE rates of CABG STEMI patients over time. In conclusion, long term survival of CABG STEMI patients is not significantly different than matched STEMI patients without prior CABG; however, CABG STEMI patients were at significantly higher risk for MACE events.

Imaging of congenital coronary anomalies with multislice computed tomography.

OBJECTIVE: To describe a single-center experience of using retrospectively gated multislice computed tomographic (MSCT) coronary angiography for imaging congenital coronary anomalies. PATIENTS AND METHODS: We retrospectively reviewed the clinical information and imaging studies for 9 patients diagnosed as having congenital coronary anomalies on invasive, selective coronary angiography between February 2001 and October 2003 at the Mayo Clinic in Jacksonville, Fla. Two experienced observers classified by consensus the origin and proximal course of the abnormal coronary arteries as seen on MSCT. RESULTS: In 1 patient, MSCT showed a normal but extremely anterior origin of the right coronary artery from the right aortic sinus of Valsalva. In the other 8 patients, the origin and course of 4 anomalous right coronary arteries, 2 anomalous left circumflex coronary arteries, and 2 single coronary arteries were recognized easily on MSCT. CONCLUSION: Similar to electron beam computed tomography and magnetic resonance imaging, widely available MSCT can characterize the proximal course of congenitally abnormal coronary arteries and thus aid in clinical decision making for patients with such anomalies.

Current results and new developments of coronary angiography with use of contrast-enhanced computed tomography of the heart.

Electron beam computed tomography (EBCT) is the reference standard for x-ray-based tomographic imaging of the heart because of its high temporal resolution, but it is available in only a few centers. Quantification of coronary calcium is the most widely recognized use of EBCT for cardiac imaging. This technique requires no contrast media and provides an accurate assessment of overall plaque burden in the coronary tree; however, it does not directly identify or localize coronary stenoses. Multislice spiral (helical) CT (MSCT) is a new technology that provides images of the beating heart in diagnostic quality under many circumstances and may facilitate the broader application of cardiac and coronary CT. Currently, for imaging of the heart, much more experience exists with EBCT than with MSCT. Contrast-enhanced CT coronary angiography (CTCA) can be done with EBCT or MSCT to obtain images of the major branches of the coronary tree and to define luminal narrowing. Studies at experienced centers performed with small numbers of patients show that sensitivity, specificity, and negative predictive value are good with CTCA in the assessment of obstructive coronary artery disease, but CTCA remains an investigational technique for these applications. Computed tomographic coronary angiography can be clinically useful for assessing coronary artery bypass graft patency and congenital coronary abnormalities.

Pseudomonas aeruginosa pseudoaneurysm of the ascending aorta after coronary artery bypass graft surgery.

Mycotic pseudoaneurysms of the ascending aorta are rare in patients undergoing coronary artery bypass graft surgery and are usually caused by Staphylococcus aureus. We describe a patient with a mycotic pseudoaneurysm of the ascending aorta at the proximal vein graft anastomosis site after coronary artery bypass grafting. Cultures from the saphenous vein harvest site and from the aneurysm sac obtained intraoperatively during repair of the pseudoaneurysm grew Pseudomonas aeruginosa. Treatment included femorofemoral bypass and hypothermic circulatory arrest with in situ patch repair. The patient was given ceftazidime and gentamicin intravenously for 2 weeks, then ceftazidime alone for 6 weeks. Thereafter, he began taking ciprofloxacin orally for chronic suppression. He was doing well at 18-month follow-up.

Image quality in a standardized algorithm for minimally invasive coronary angiography with multislice spiral computed tomography.

PURPOSE: To report our experience with a standardized approach to pharmacologic heart rate control and image postprocessing for computed tomographic coronary angiography (CTCA) with multislice computed tomography (MSCT). METHOD: Two experienced observers used transaxial tomograms and maximum-intensity projections to classify coronary segments (12 per patient, 135 consecutive patients) for degree of stenosis. One factor affecting image quality was identified for each segment that could not be assessed. RESULTS: Nine patients (7%) were excluded for technical reasons. Of 1,512 segments from 126 patients, 1,086 (72%) were assessable (8.6 per patient). Of 300 segments from 25 patients who also had selective coronary angiography, CTCA was able to assess 211 (70%) and detected significant disease in 27 (82% sensitivity, 96% specificity, 73% positive predictive value, and 97% negative predictive value). Vessel caliber, heart rate, and Agatston score were associated with inability to assess 426 coronary segments (28%). CONCLUSION: Heart rate and Agatston score are important predictors of the ability to assess proximal and midcoronary segments by CTCA with MSCT.